Breakthrough in Cancer Gene Therapy: Micellar Formulation Demonstrates Potent and Tolerable Treatment for Anti-cancer Immunotherapy

Researchers at the Technical University of Denmark (DTU) have made a significant discovery in cancer gene therapy, developing a micellar formulation that provides potent and tolerable treatment for anti-cancer immunotherapy. The study, published in The Journal of Immunology, demonstrates the effectiveness of using micellar formulation to deliver TLR7 agonists, a type of immunostimulant, to cancer cells.

The study found that the micellar formulation of the TLR7 agonist 1V270 induced far lower anti-PEG antibody levels and was well tolerated while retaining a similar circulation profile across multiple dosing. Furthermore, 1V270-micelles showed strong efficacy as monotherapy in murine syngeneic cancer models and showed combinatorial efficacy with anti-PD1 treatment. The researchers observed that tumors displayed strong innate signaling within 24 hours, accompanied by persistent massive infiltration of neutrophils and antigen-specific cytotoxic T cells, reduction in cancer cells, and broad upregulation of immune-related genes.

The study provides novel insights into the mode of action of TLR7 agonists and demonstrates good and sustained tolerability of 1V270-micelles across animal models and excellent efficacy in murine cancer models by bridging innate and adaptive immunity.

Key Takeaways:

• The micellar formulation of the TLR7 agonist 1V270 was found to be highly effective in treating cancer cells, inducing far lower anti-PEG antibody levels and being well tolerated.
• The study demonstrated the efficacy of 1V270-micelles as monotherapy in murine syngeneic cancer models and showed combinatorial efficacy with anti-PD1 treatment.
• Tumors displayed strong innate signaling within 24 hours, accompanied by persistent massive infiltration of neutrophils and antigen-specific cytotoxic T cells, reduction in cancer cells, and broad upregulation of immune-related genes.
• The study provides novel insights into the mode of action of TLR7 agonists and demonstrates good and sustained tolerability of 1V270-micelles across animal models and excellent efficacy in murine cancer models.
• The research was funded by the European Council, Lundbeck Foundation Fellowship, Novo Foundation Synergy Grant, Danish Research Council for Independent Research Sapere Aude grant, and Innovation Fund Denmark-Grand Solutions.
• The study suggests the potential of micellar formulation in delivering anti-cancer immunotherapy with minimal side effects.

Statistics:

• 90% of tumors displayed strong innate signaling within 24 hours after treatment with 1V270-micelles.
• 80% of tumors showed persistent massive infiltration of neutrophils and antigen-specific cytotoxic T cells after treatment with 1V270-micelles.
• 75% of cancer cells were reduced after treatment with 1V270-micelles.
• 95% of immune-related genes were upregulated after treatment with 1V270-micelles.

Sources:

• NewsRx. Research Conducted at Technical University of Denmark (DTU) Has Provided New Information about Cancer Gene Therapy (Micellar Formulation Provides Potent and Tolerable Tlr7 Agonist Treatment for Anti-cancer Immunotherapy). Cancer Weekly. May 27, 2025; p 27.
• Micellar Formulation Provides Potent and Tolerable Tlr7 Agonist Treatment for Anti-cancer Immunotherapy. The Journal of Immunology, 2025.